A study by Canadian researchers suggests that 43.5 percent of patients who began using medical cannabis to mitigate harmful alcohol habits were able to reduce the frequency of their alcohol use or quit entirely.

Markets are tumbling. Where do you want to be positioned AFTER the selloff is over? Psychedelic stocks.

Field Trip’s new psychedelic molecule, FT-104, is showing similar efficacy to psychedelics like psilocybin — but with shorter duration.

With MindMed’s latest financing, total cash reserves now stand at CAD$50.1 million.

Nevada’s recreational marijuana sales have largely recovered, having slumped in the spring from some of the strictest coronavirus shutdown measures in the nation and dwindling numbers of tourists visiting Las Vegas.

Champignon Brands is hopeful that the B.C. Securities Commission is close to revoking its Cease Trade Order for SHRM.

M2Bio Sciences (Wuhan General Group) has finalized an agreement with the University of Pretoria (South Africa) to conduct a psilocybin-based clinical trial.

The US Department of Agriculture (USDA) on Thursday approved Indiana’s hemp plan – its third approved plan over the last week.

If New Jersey voters approve a marijuana legalization referendum on their ballots next week, sales in the Garden State could get rolling at record speed.

Fitness wearables company, Hapbee Technologies, is going to commence trading October 30th on the TSX Venture Exchange (symbol “HAPB”).